NovAccel, Inc., a Japanese deep-tech company developing proprietary superconducting accelerator technology for medical radioisotope production, has announced that its project to establish a new actinium-225 (Ac-225) manufacturing facility in Namie, Fukushima Prefecture, has been selected for support under a subsidy programme administered by Japan’s Ministry of Economy, Trade and Industry (METI).
The subsidy will support the construction of a new medical radioisotope manufacturing facility utilising NovAccel’s proprietary compact superconducting electron accelerator technology, as part of METI’s program to promote business investment and job creation in Fukushima.
Expanding Global Supply of Actinium-225Targeted alpha therapy (TAT) is emerging as a promising approach to cancer treatment, with the potential to deliver highly potent radiation selectively to cancer cells while limiting damage to surrounding healthy tissue.
Ac-225, a key isotope used in the development of targeted alpha therapies, is experiencing rapidly growing demand as pharmaceutical companies advance clinical development programmes. However, limited global production capacity remains a significant constraint on the development and future commercialisation of these therapies.
NovAccel is developing RiSA (Radio-isotope production Superconducting Accelerator), a proprietary compact superconducting accelerator platform designed to enable efficient and scalable production of medical radioisotopes.
Following its initial facility in Hiroshima, NovAccel plans to establish one of the world’s largest commercial-scale Ac-225 manufacturing facilities in Namie, Fukushima. The new facility will deploy RiSA technology to expand global production capacity and support a reliable supply of high-quality Ac-225 for the growing radiopharmaceutical market.
